A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

These glucose effects remained consistent throughout the weekly dosing cycle. Subjects were randomized to receive five weekly injections of 0.05, 0.3, 1, 3, 5 or 8 mg of dulaglutide. At the end of ...